Results 181 to 190 of about 518,198 (339)

EGR1 Nuclear Condensates Promote Renal Cyst Development in Polycystic Kidney Disease

Exploration, EarlyView.
ABSTRACT Autosomal dominant polycystic kidney disease (ADPKD) is marked by aberrant cell proliferation driven by cAMP‐PKA and MAPK signaling pathways. EGR1, a transcription factor directly activated by the above two pathways, is critical in the over‐proliferation of tumor cells, which share similarities with cystic epithelial cells in ADPKD. This study
Chaoqun Ren, Zhaoxu Wu, Min Li, Yaqin Du, Hong Zhou, Yazhu Quan, Mengyao Xiong, Yiming Wang, Zhiwei Qiu, Shuai Zhu, Xiaowei Li, Jinzhao He, Cai Gao, Hui Cai, Tingting Li, Baoxue Yang   +15 more
wiley   +1 more source

Dual blockade of lipid and cyclin-dependent kinases induces synthetic lethality in malignant glioma [PDF]

, 2012
Christine Cheng, W. Clay Gustafson, Elizabeth Charron, Benjamin T. Houseman, Eli R. Zunder, Andrei Goga, Nathanael S. Gray, Brian A. Pollok, Scott A. Oakes, C. David James, Kevan M. Shokat, William A. Weiss, Qi‐Wen Fan   +12 more
openalex   +1 more source

Metastatic Cutaneous Adnexal Carcinoma of the Head and Neck With Durable Response to an Aromatase Inhibitor Combined With a Cyclin‐Dependent Kinase 4/6 Inhibitor

Head &Neck, EarlyView.
ABSTRACT Background Cutaneous adnexal carcinomas are a very rare group of cancers arising from appendageal structures of the skin. More than half occur in the head and neck region. No standard treatments exist for metastatic disease. Methods A 48‐year‐old postmenopausal female presented with an enlarging scalp lesion.
Nilesh Kapoor, Manasa Narasimman, Travis Vandergriff, Amy L. Jones   +3 more
wiley   +1 more source

The T-box transcription factor TBX3 drives proliferation by direct repression of the p21WAF1 cyclin-dependent kinase inhibitor [PDF]

, 2016
Tarryn Willmer, Shannagh Hare, Jade Peres, Sharon Prince   +3 more
openalex   +1 more source

Cyclin-Dependent Kinase Inhibitors as Anticancer Therapeutics

Molecular Pharmacology, 2015
Mary E. Law, P. Corsino, S. Narayan, B. Law   +3 more
semanticscholar   +1 more source

Palbociclib can overcome mutations in cyclin dependent kinase 6 that break hydrogen bonds between the drug and the protein [PDF]

, 2017
Stella H. Maganhi, Patrizia Jensen, Ignez Caracelli, J. Zukerman‐Schpector, Stefan Fröhling, Ran Friedman   +5 more
openalex   +1 more source

D-type cyclin-dependent kinase activity in mammalian cells

Molecular and Cellular Biology, 1994
H. Matsushime, D. Quelle, S. Shurtleff, M. Shibuya, C. Sherr, J. Kato   +5 more
semanticscholar   +1 more source

1,7-Annulated indolocarbazoles as cyclin-dependent kinase inhibitors

, 2004
Rima Al‐awar, James E. Ray, Kyle A. Hecker, Jianping Huang, Philip P. Waid, Chuan Shih, Harold B. Brooks, Charles D. Spencer, Scott A. Watkins, Bharvin Patel, Nancy B. Stamm, Catherine A. Ogg, Richard M. Schultz, Eileen L. Considine, Margaret M. Faul, Kevin A. Sullivan, Stanley P. Kolis, John L. Grutsch, Sajan Joseph   +18 more
openalex   +1 more source

Enhanced Growth of Mice Lacking the Cyclin-Dependent Kinase Inhibitor Function of p27 Kip1

Cell, 1996
H. Kiyokawa, R. Kineman, K. Manova-Todorova, V. Soares, E. S. Hoffman, M. Ono, Dilruba Khanam, A. Hayday, L. Frohman, A. Koff   +9 more
semanticscholar   +1 more source

Somatic cell reprogramming for Parkinson's disease treatment

Ibrain, Volume 11, Issue 1, Page 59-73, Spring 2025.
The fundamental purpose of cell reprogramming to treat Parkinson's disease is to generate dopaminergic neurons (DAN) and do transplantation. There are two ways to accomplish this. One method is to induce cells into induced DA neurons (iDAN) directly or to induce cells into induced pluripotent stem cells and ultimately into iDAN in vitro. Another option
Xiaozhuo Li, Kevin Fang, Fengping Wang
wiley   +1 more source